This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
staphylococcus aureus | 288 |
node length | 256 |
length cov | 256 |
virsorter node | 256 |
cat virsorter | 241 |
genome sequence | 230 |
infectious bronchitis | 226 |
clinical isolates | 220 |
escherichia coli | 207 |
amino acid | 194 |
respiratory tract | 175 |
clinical signs | 174 |
bronchitis virus | 156 |
lg ml | 151 |
antibiotic resistance | 150 |
resistant strains | 141 |
complete genome | 139 |
mg kg | 134 |
sequence accession | 131 |
strains isolated | 129 |
infectious diseases | 126 |
present study | 121 |
mg ml | 120 |
phylogenetic analysis | 120 |
antimicrobial agents | 117 |
pseudomonas aeruginosa | 110 |
laboratory mice | 109 |
susceptibility testing | 103 |
vitro activity | 102 |
infected mice | 102 |
ibv strains | 99 |
streptococcus pneumoniae | 99 |
antimicrobial resistance | 99 |
closely related | 97 |
performed using | 96 |
blood cultures | 95 |
intensive care | 95 |
risk factors | 93 |
immunodeficient mice | 90 |
ck ch | 89 |
urinary tract | 89 |
amino acids | 88 |
tract infections | 88 |
immune response | 87 |
time pcr | 85 |
virus infection | 84 |
mcg ml | 84 |
chain reaction | 83 |
resistance genes | 80 |
clostridium difficile | 80 |
litter size | 79 |
gene expression | 79 |
polymerase chain | 79 |
resistant staphylococcus | 79 |
agar dilution | 78 |
gel electrophoresis | 78 |
united states | 77 |
public health | 74 |
antibiotic treatment | 73 |
mean age | 73 |
disk diffusion | 73 |
hepatitis virus | 72 |
antibiotic therapy | 71 |
immune system | 70 |
control group | 70 |
cell lines | 69 |
cfu ml | 69 |
sequence analysis | 68 |
results showed | 68 |
mic values | 68 |
significant differences | 67 |
negative bacteria | 65 |
broth microdilution | 64 |
resistant isolates | 64 |
antimicrobial susceptibility | 64 |
strain srs | 64 |
spinal cord | 64 |
clinical trials | 64 |
immune responses | 63 |
lymph nodes | 63 |
mouse hepatitis | 63 |
determined using | 62 |
infection control | 62 |
laboratory animal | 62 |
genetic diversity | 62 |
two strains | 62 |
blood culture | 61 |
immunocompetent mice | 60 |
three different | 59 |
avian infectious | 59 |
broad spectrum | 58 |
pcr assay | 58 |
infections caused | 58 |
statistically significant | 58 |
commonly used | 57 |
bone marrow | 57 |
blood samples | 57 |
infectious disease | 57 |
drug resistance | 57 |
bactericidal activity | 56 |
significant difference | 56 |
year period | 56 |
mic mg | 55 |
nervous system | 55 |
mrsa isolates | 55 |
two different | 55 |
care unit | 55 |
may occur | 55 |
lactic acid | 55 |
differential diagnosis | 55 |
university hospital | 54 |
scid mice | 54 |
probiotic strains | 53 |
important role | 52 |
results obtained | 52 |
mouse colonies | 52 |
diffusion method | 52 |
previously described | 52 |
clavulanic acid | 52 |
research complications | 52 |
soft tissue | 52 |
agar plates | 51 |
antibiotic susceptibility | 51 |
reduced susceptibility | 51 |
dilution method | 51 |
etec strains | 50 |
study period | 50 |
antimicrobial therapy | 50 |
mice infected | 50 |
negative staphylococci | 50 |
mice may | 50 |
genome sequences | 50 |
sendai virus | 50 |
adverse events | 50 |
minute virus | 49 |
mrsa strains | 49 |
adult mice | 49 |
field gel | 49 |
viral load | 49 |
rrna gene | 49 |
nosocomial infections | 49 |
cell culture | 49 |
airway caliber | 49 |
klebsiella pneumoniae | 48 |
experimental infection | 48 |
may also | 48 |
draft genome | 48 |
recombination events | 48 |
asm strain | 48 |
tract infection | 48 |
recent years | 48 |
porcine epidemic | 48 |
one patient | 48 |
central nervous | 48 |
virulence factors | 48 |
clinical disease | 47 |
nrtw i | 47 |
lymphocytic choriomeningitis | 47 |
helicobacter pylori | 47 |
resistance rates | 47 |
log cfu | 47 |
significantly higher | 47 |
clinical microbiology | 47 |
two groups | 47 |
animal medicine | 46 |
last years | 46 |
chemical engineering | 46 |
results suggest | 46 |
susceptible strains | 46 |
macrolide resistance | 46 |
mouse strains | 46 |
airway wall | 46 |
clinical samples | 45 |
doc id | 45 |
one hundred | 45 |
bacillus subtilis | 45 |
lung volume | 45 |
cell wall | 45 |
antibacterial activity | 45 |
antibiotic use | 45 |
viral rna | 45 |
cord uid | 45 |
nccls guidelines | 44 |
years old | 44 |
high level | 44 |
epidemic diarrhea | 44 |
inbred strains | 44 |
pcr assays | 43 |
epithelial cells | 43 |
species level | 43 |
drug resistant | 43 |
reference strains | 43 |
herpes simplex | 43 |
bl mice | 43 |
heavy metal | 42 |
mortality rate | 42 |
genes encoding | 42 |
positive bacteria | 42 |
smooth muscle | 42 |
aureus isolates | 42 |
spectrum beta | 42 |
blood agar | 41 |
choriomeningitis virus | 41 |
additional file | 41 |
wide range | 41 |
gross lesions | 41 |
piperacillin tazobactam | 41 |
high prevalence | 41 |
least one | 40 |
patients received | 40 |
aureus strains | 40 |
multiplex pcr | 40 |
virus strain | 40 |
nucleotide sequence | 40 |
hospitalized patients | 40 |
auc mic | 39 |
large number | 39 |
per patient | 39 |
bacterial meningitis | 39 |
viral infections | 39 |
generation cephalosporins | 39 |
lower respiratory | 39 |
candida spp | 39 |
interspecies transmission | 39 |
bacterial pathogens | 39 |
innate immune | 39 |
antimicrobial activity | 39 |
healthy volunteers | 39 |
inhibitory concentration | 39 |
vaccine strain | 38 |
gram negative | 38 |
pcr products | 38 |
diarrhea virus | 38 |
type strains | 38 |
plasmodium falciparum | 38 |
positive strains | 38 |
drinking water | 38 |
pk pd | 38 |
saccharomyces cerevisiae | 38 |
bacterial strains | 38 |
results indicate | 38 |
lactate dehydrogenase | 38 |
molecular epidemiology | 38 |
coli strains | 37 |
pregnant women | 37 |
widely used | 37 |
enterococcus faecalis | 37 |
health care | 37 |
clinical strains | 37 |
small intestine | 37 |
bacterial infections | 37 |
strains showed | 37 |
resistance among | 37 |
genomic dna | 37 |
gastrointestinal tract | 37 |
nucleic acid | 36 |
acquired pneumonia | 36 |
growth rate | 36 |
viral replication | 36 |
coding region | 36 |
multiple sclerosis | 36 |
recombinant proteins | 36 |
carbon source | 36 |
one case | 36 |
haemophilus influenzae | 36 |
cell cultures | 36 |
one isolate | 36 |
tissue infections | 36 |
positive samples | 35 |
wild type | 35 |
respiratory disease | 35 |
results show | 35 |
cell line | 35 |
two patients | 35 |
ch lhlj | 35 |
well tolerated | 35 |
high mortality | 35 |
simplex virus | 35 |
laboratory rats | 35 |
three strains | 35 |
reference strain | 35 |
respiratory infections | 35 |
acute respiratory | 35 |
genome sequencing | 34 |
mass spectrometry | 34 |
antiviral activity | 34 |
strain hun | 34 |
anaerobic bacteria | 34 |
i strain | 34 |
serum samples | 34 |
natural infection | 34 |
pneumoniae isolates | 34 |
patients treated | 34 |
may develop | 33 |
molecular typing | 33 |
citric acid | 33 |
upper respiratory | 33 |
laboratory mouse | 33 |
quinupristin dalfopristin | 33 |
age group | 33 |
also found | 33 |
persistent infection | 33 |
clinical specimens | 33 |
molecular biology | 33 |
risk factor | 33 |
minimum inhibitory | 33 |
cerebrospinal fluid | 33 |
acinetobacter baumannii | 33 |
strains belonging | 33 |
technical university | 33 |
microdilution method | 33 |
infant mice | 33 |
virulence genes | 33 |
north america | 32 |
canine astvs | 32 |
stool samples | 32 |
water buffalo | 32 |
phylogenetic tree | 32 |
type i | 32 |
patients receiving | 32 |
whole genome | 32 |
gene sequence | 32 |
infected animals | 32 |
metabolic engineering | 32 |
coli isolates | 32 |
pcr amplification | 32 |
one strain | 32 |
species identification | 32 |
different strains | 32 |
molecular characterization | 32 |
phylogenetic trees | 32 |
commercially available | 32 |
direct contact | 32 |
ectromelia virus | 32 |
dm strain | 31 |
per cent | 31 |
hospital stay | 31 |
mouse strain | 31 |
resistant bacteria | 31 |
teaching hospital | 31 |
faecal samples | 31 |
naturally occurring | 31 |
acid production | 31 |
respiratory syndrome | 31 |
analysis showed | 31 |
two isolates | 31 |
positive blood | 31 |
data suggest | 31 |
clinical trial | 31 |
quality control | 30 |
fecal samples | 30 |
study showed | 30 |
biofilm formation | 30 |
animal models | 30 |
salmonella spp | 30 |
experimentally infected | 30 |
inbred strain | 30 |
three patients | 30 |
murine norovirus | 30 |
infections due | 30 |
resistance determinants | 30 |
klebsiella spp | 30 |
methicillin resistant | 30 |
mg bid | 29 |
viral infection | 29 |
fermentation process | 29 |
reverse transcriptase | 29 |
infected patients | 29 |
total number | 29 |
spike gene | 29 |
airway smooth | 29 |
extended spectrum | 29 |
deep inspiration | 29 |
time points | 29 |
wild mice | 29 |
serratia marcescens | 29 |
acinetobacter spp | 29 |
strain i | 29 |
biological materials | 29 |
virus type | 29 |
life cycle | 28 |
canine coronavirus | 28 |
collaborative cross | 28 |
clinical studies | 28 |
serological tests | 28 |
previous studies | 28 |
recombinant protein | 28 |
enterococcus spp | 28 |
hospitalised patients | 28 |
patients admitted | 28 |
real time | 28 |
antibiotics tested | 28 |
mouse model | 28 |
cystic fibrosis | 28 |
vaccine strains | 28 |
disease virus | 28 |
european countries | 28 |
stem cells | 28 |
candida species | 28 |
virus strains | 27 |
infectious agents | 27 |
ankara university | 27 |
molecular methods | 27 |
several studies | 27 |
embryo transfer | 27 |
middle ear | 27 |
nucleotide sequences | 27 |
acid sequences | 27 |
analysis revealed | 27 |
negative bacilli | 27 |
bacterial infection | 27 |
mic mic | 27 |
gene encoding | 27 |
genes involved | 27 |
oxygen transfer | 27 |
three groups | 27 |
resistance phenotypes | 27 |
internal medicine | 27 |
causative agent | 27 |
differentially expressed | 27 |
dna sequencing | 27 |
elevating virus | 27 |
described previously | 26 |
community acquired | 26 |
type strain | 26 |
mouse parvovirus | 26 |
may cause | 26 |
bat rva | 26 |
nt identity | 26 |
helicobacter spp | 26 |
icu patients | 26 |
producing strains | 26 |
electron microscopy | 26 |
ndm strain | 26 |
antibiotic consumption | 26 |
influenza virus | 26 |
complicated skin | 26 |
cell proliferation | 26 |
yeast extract | 26 |
inclusion bodies | 26 |
recent studies | 26 |
specific primers | 26 |
study group | 26 |
high risk | 26 |
nalidixic acid | 26 |
tetracycline resistance | 26 |
resistance patterns | 26 |
positive isolates | 26 |
protein expression | 26 |
clinical features | 26 |
predictive value | 26 |
enzyme activity | 26 |
enterococcus faecium | 26 |
th day | 26 |
encephalomyelitis virus | 25 |
method according | 25 |
bacterial growth | 25 |
significant increase | 25 |
resistance phenotype | 25 |
decreased susceptibility | 25 |
gut microbiota | 25 |
resistance mechanisms | 25 |
class i | 25 |
heavy metals | 25 |
treated patients | 25 |
pfspz strains | 25 |
neonatal mice | 25 |
respiratory pathogens | 25 |
lhlj vii | 25 |
mrsa infections | 25 |
ibv strain | 25 |
gram positive | 25 |
positive cocci | 25 |
accession numbers | 25 |
structural proteins | 25 |
performed according | 25 |
age groups | 25 |
enteric viruses | 25 |
rna viruses | 25 |
spike protein | 25 |
clinically relevant | 25 |
medical microbiology | 25 |
diabetes mellitus | 25 |
virus isolation | 25 |
room temperature | 25 |
monoclonal antibodies | 25 |
major cause | 25 |
analysed using | 24 |
ml min | 24 |
flow cytometry | 24 |
negative rods | 24 |
rabbit haemorrhagic | 24 |
antibody response | 24 |
among patients | 24 |
first time | 24 |
molecular weight | 24 |
genital tract | 24 |
immunocompromised patients | 24 |
streptococcus pyogenes | 24 |
disc diffusion | 24 |
natural infections | 24 |
mesenteric lymph | 24 |
ch ldl | 24 |
pathogenic bacteria | 24 |
clinical data | 24 |
severe infections | 24 |
statistical analysis | 24 |
strain infection | 24 |
high rate | 24 |
pneumonia virus | 24 |
multidrug resistant | 24 |
five patients | 24 |
sex ratio | 24 |
significantly increased | 24 |
bronchitis coronavirus | 24 |
control measures | 24 |
different species | 24 |
mg dl | 24 |
like virus | 24 |
severe sepsis | 24 |
infective endocarditis | 24 |
laboratory animals | 24 |
athymic mice | 24 |
fatty acids | 24 |
haemorrhagic disease | 24 |
acute infection | 24 |
days post | 24 |
clinical cure | 24 |
otitis media | 24 |
pg ml | 24 |
host cells | 24 |
clinical response | 23 |
spf chicken | 23 |
care units | 23 |
single dose | 23 |
case report | 23 |
avian coronavirus | 23 |
acid sequence | 23 |
mycoplasma pulmonis | 23 |
low level | 23 |
structure infections | 23 |
binary toxin | 23 |
may result | 23 |
infl uenza | 23 |
acute diarrhea | 23 |
two cases | 23 |
nitric oxide | 23 |
mus musculus | 23 |
lung volumes | 23 |
inhibitory concentrations | 23 |
pedv strain | 23 |
mononuclear cells | 23 |
staphylococcus epidermidis | 23 |
reverse transcription | 23 |
expression levels | 23 |
antifungal therapy | 23 |
deficient mice | 23 |
prkdc scid | 23 |
secondary metabolites | 23 |
six patients | 23 |
aspergillus niger | 23 |
immunosorbent assay | 23 |
highly conserved | 23 |
analyzed using | 23 |
positive results | 23 |
general hospital | 23 |
situ hybridization | 23 |
healthy subjects | 23 |
high degree | 23 |
suckling mice | 23 |
associated diarrhoea | 23 |
resistance rate | 23 |
strains tested | 23 |
typhimurium strains | 23 |
high levels | 23 |
open reading | 23 |
target protein | 22 |
high resistance | 22 |
negative control | 22 |
hinton agar | 22 |
imi cis | 22 |
supplementary material | 22 |
capsid protein | 22 |
analysis using | 22 |
group i | 22 |
control study | 22 |
foxn nu | 22 |
different groups | 22 |
amoxicillin clavulanate | 22 |
helicobacter species | 22 |
shiga toxin | 22 |
acid substitutions | 22 |
among children | 22 |
four strains | 22 |
retrospective study | 22 |
strains may | 22 |
acid bacteria | 22 |
national institute | 22 |
per year | 22 |
chicken eggs | 22 |
transplant recipients | 22 |
three isolates | 22 |
side effects | 22 |
peripheral blood | 22 |
patients infected | 22 |
acute gastroenteritis | 22 |
may lead | 22 |
sequence data | 22 |
also observed | 22 |
rna polymerase | 22 |
intestinal tract | 22 |
serum concentrations | 22 |
old spf | 22 |
pcr method | 22 |
genomic sequences | 22 |
body weight | 22 |
findings suggest | 22 |
empiric therapy | 22 |
bacterial isolates | 22 |
preliminary results | 21 |
candida albicans | 21 |
naturally infected | 21 |
skeletal muscle | 21 |
mg iv | 21 |
nude mice | 21 |
copies ml | 21 |
adult patients | 21 |
esbl production | 21 |
associated pneumonia | 21 |
bloodstream infections | 21 |
abdominal pain | 21 |
salivary glands | 21 |
host range | 21 |
microbiology laboratories | 21 |
infection may | 21 |
clinical success | 21 |
carbon sources | 21 |
isolates collected | 21 |
using pcr | 21 |
erythromycin resistance | 21 |
three times | 21 |
accession jx | 21 |
determine whether | 21 |
logistic regression | 21 |
normal mice | 21 |
buffalo calves | 21 |
middle east | 21 |
organic acids | 21 |
within days | 21 |
vitro susceptibility | 21 |
isolated strains | 21 |
urine samples | 21 |
different time | 21 |
dna sequences | 21 |
weight loss | 21 |
human rhinovirus | 21 |
even though | 21 |
hbv dna | 21 |
monoclonal antibody | 21 |
resistance gene | 21 |
developing countries | 21 |
identified using | 21 |
also may | 21 |
enzyme immunoassay | 20 |
data obtained | 20 |
bacillus anthracis | 20 |
research institute | 20 |
severe acute | 20 |
pneumoniae strains | 20 |
esbl producing | 20 |
pylori infection | 20 |
molecular analysis | 20 |
genetic relatedness | 20 |
prospective study | 20 |
tertiary care | 20 |
mice develop | 20 |
previously reported | 20 |
norovirus infection | 20 |
plasma concentrations | 20 |
fusidic acid | 20 |
applied biosystems | 20 |
united kingdom | 20 |
frequently used | 20 |
linked immunosorbent | 20 |
pv strains | 20 |
clinical isolate | 20 |
specific antibodies | 20 |
patients hospitalised | 20 |
difficile strains | 20 |
persistently infected | 20 |
ldl i | 20 |
four different | 20 |
protein binding | 20 |
rna virus | 20 |
group ii | 20 |
staphylococcus spp | 20 |
i i | 20 |
underlying disease | 20 |
relatively low | 20 |
inbred mice | 20 |
oral administration | 20 |
young children | 20 |
gc gc | 20 |
resistant gram | 20 |
accession cp | 20 |
eltab operon | 19 |
crude extracts | 19 |
bacteria isolated | 19 |
tested using | 19 |
significantly different | 19 |
highly susceptible | 19 |
murine cytomegalovirus | 19 |
specific pcr | 19 |
obtained using | 19 |
strains used | 19 |
acute phase | 19 |
difficile infection | 19 |
es cells | 19 |
mhv infection | 19 |
pedv strains | 19 |
plates containing | 19 |
helicobacter hepaticus | 19 |
gene sequences | 19 |
selective pressure | 19 |
medium composition | 19 |
stranded rna | 19 |
highly resistant | 19 |
antibody production | 19 |
month period | 19 |
pcr using | 19 |
clinical symptoms | 19 |
rva strains | 19 |
rotavirus infection | 19 |
antifungal agents | 19 |
cell growth | 19 |
bronchodilator effect | 19 |
polish ibv | 19 |
among strains | 19 |
serratia sp | 19 |
clinical manifestations | 19 |
recently described | 19 |
different types | 19 |
susceptibility tests | 19 |
natural products | 19 |
mic ratio | 19 |
skin structure | 19 |
environmental conditions | 19 |
cure rates | 19 |
experimental inoculation | 19 |
well known | 19 |
clinical efficacy | 18 |
stationary phase | 18 |
therapeutic option | 18 |
amoxicillin clavulanic | 18 |
pseudomonas sp | 18 |
currently available | 18 |
disease caused | 18 |
host cell | 18 |
lt expression | 18 |
central laboratory | 18 |
airway distensibility | 18 |
distantly related | 18 |
respiratory viruses | 18 |
kg day | 18 |
mouse models | 18 |
patients without | 18 |
glycopeptide resistance | 18 |
previously published | 18 |
using standard | 18 |
transplantable tumors | 18 |
clinical significance | 18 |
acquired infections | 18 |
six strains | 18 |
several weeks | 18 |
skin lesions | 18 |
excellent activity | 18 |
internal control | 18 |
genomic analysis | 18 |
calculated using | 18 |
medical centres | 18 |
critically ill | 18 |
igg antibodies | 18 |
western europe | 18 |
bacterial species | 18 |
enterobacter spp | 18 |
using different | 18 |
phase i | 18 |
fungal infections | 18 |
methods used | 18 |
conventional methods | 18 |
interpreted according | 18 |
studies using | 18 |
negative strains | 18 |
gastric cancer | 18 |
large scale | 18 |
high frequency | 18 |
mortality rates | 18 |
significantly lower | 18 |
hong kong | 18 |
hcv rna | 18 |
septic shock | 18 |
highly contagious | 18 |
nucleotide changes | 18 |
product formation | 18 |
lethal infection | 18 |
gene cluster | 18 |
susceptible strain | 18 |
anaerobic conditions | 18 |
commensal bacteria | 18 |
nitrogen sources | 18 |
enterotoxigenic escherichia | 18 |
typing methods | 18 |
tissue tropism | 18 |
enzyme production | 18 |
western blot | 18 |
nosocomial pneumonia | 18 |
resistant strain | 18 |
ccov strains | 18 |
antigen detection | 18 |
recent study | 17 |
astrovirus infection | 17 |
infected colonies | 17 |
pancreatic tissue | 17 |
new class | 17 |
strain isolated | 17 |
mouse adenovirus | 17 |
important factor | 17 |
salmonella isolates | 17 |
including methicillin | 17 |
seven patients | 17 |
vp region | 17 |
sequencing data | 17 |
experimental studies | 17 |
infected cells | 17 |
flaccid paralysis | 17 |
ab biodisk | 17 |
nucleotide identity | 17 |
avian species | 17 |
laboratory rodents | 17 |
dairy products | 17 |
asm undergoes | 17 |
gold standard | 17 |
strain infected | 17 |
constructed using | 17 |
lesser mealworm | 17 |
northeast china | 17 |
low prevalence | 17 |
better understand | 17 |
inflammatory response | 17 |
two hundred | 17 |
spf chickens | 17 |
yc pedv | 17 |
chronic infection | 17 |
flow rate | 17 |
mg day | 17 |
may provide | 17 |
third generation | 17 |
two main | 17 |
genetic analysis | 17 |
plasmid dna | 17 |
listeria monocytogenes | 17 |
test results | 17 |
randomly selected | 17 |
like viruses | 17 |
kill curves | 17 |
genomic sequence | 17 |
sheep blood | 17 |
ddd tid | 17 |
expression level | 17 |
bifi dobacterium | 17 |
wide variety | 17 |
type ii | 17 |
north american | 17 |
common pathogens | 17 |
per day | 17 |
heterologous chmi | 17 |
patient days | 17 |
hiv infection | 17 |
apache ii | 17 |
positive cultures | 17 |
faecium isolates | 17 |
salmonella enterica | 17 |
resistant enterococci | 17 |
rapid detection | 17 |
genetically modified | 17 |
point mutations | 17 |
serious infections | 17 |
detection methods | 17 |
fragment length | 17 |
sequence identity | 17 |
level resistance | 17 |
czech republic | 17 |
intestinal microbiota | 17 |
showed high | 17 |
median age | 17 |
isolates showed | 17 |
airway tree | 17 |
vancomycin resistance | 17 |
young mice | 17 |
isolates recovered | 17 |
fold higher | 16 |
spectrum activity | 16 |
infection rate | 16 |
nosocomial infection | 16 |
treatment failure | 16 |
protein production | 16 |
ascorbic acid | 16 |
host species | 16 |
genbank database | 16 |
viral antigen | 16 |
proteus mirabilis | 16 |
laboratory using | 16 |
retention time | 16 |
different methods | 16 |
human strains | 16 |
prosthetic valve | 16 |
accession jq | 16 |
renal function | 16 |
nt long | 16 |
antibiotic concentrations | 16 |
gene sequencing | 16 |
current study | 16 |
meningococcal disease | 16 |
also used | 16 |
hair coat | 16 |
relatively high | 16 |
frequently isolated | 16 |
different regions | 16 |
protease inhibitors | 16 |
ethanol production | 16 |
russian federation | 16 |
lcmv infection | 16 |
tg mice | 16 |
nose inoculation | 16 |
demyelinating disease | 16 |
common cause | 16 |
virus replication | 16 |
bacteroides fragilis | 16 |
intracerebral inoculation | 16 |
vp gene | 16 |
cov gc | 16 |
neurological signs | 16 |
outer membrane | 16 |
resistance pattern | 16 |
significant reduction | 16 |
susceptible mice | 16 |
respiratory syncytial | 16 |
positive control | 16 |
hinton broth | 16 |
antifungal susceptibility | 16 |
strain ck | 16 |
may represent | 16 |
highly divergent | 16 |
human health | 16 |
membrane protein | 16 |
year old | 16 |
mammalian species | 16 |
parental strain | 16 |
quinolone resistance | 16 |
similar results | 16 |
chicken flocks | 16 |
early diagnosis | 16 |
acute disease | 16 |
valentine leukocidin | 16 |
five isolates | 16 |
negative predictive | 16 |
also showed | 16 |
microdilution panels | 16 |
new zealand | 16 |
treatment groups | 16 |
five strains | 16 |
lactam antibiotics | 16 |
limited number | 16 |
surveillance program | 16 |
salivary gland | 16 |
clinical laboratory | 16 |
agglutination test | 16 |
viral genome | 16 |
fatty acid | 16 |
results demonstrate | 16 |
sequence typing | 16 |
reading frames | 16 |
rva bat | 16 |
health surveillance | 16 |
coagulase negative | 16 |
trimethoprim sulfamethoxazole | 16 |
comparative study | 16 |
synergy test | 16 |
vero cells | 16 |
length polymorphism | 16 |
double disk | 16 |
subjects received | 16 |
different genotypes | 16 |
clinically significant | 16 |
twice daily | 16 |
done using | 16 |
antimicrobial prophylaxis | 16 |
times higher | 16 |
high throughput | 15 |
four patients | 15 |
mouse populations | 15 |
environmental factors | 15 |
nu mice | 15 |
class integrons | 15 |
vaccinia virus | 15 |
controlled trial | 15 |
investigated using | 15 |
vitro studies | 15 |
first report | 15 |
common among | 15 |
three cases | 15 |
syncytial virus | 15 |
major role | 15 |
dilution rate | 15 |
health problem | 15 |
causative organisms | 15 |
serratia spp | 15 |
bowel disease | 15 |
resistance profile | 15 |
lactobacillus casei | 15 |
growth conditions | 15 |
complete genomic | 15 |
transgenic mice | 15 |
cell epitopes | 15 |
vitek system | 15 |
elderly patients | 15 |
authors declare | 15 |
cost per | 15 |
host immune | 15 |
metabolic pathways | 15 |
combination therapy | 15 |
mass transfer | 15 |
producing enterobacteriaceae | 15 |
capsid region | 15 |
experimental model | 15 |
least two | 15 |
penicillin resistant | 15 |
nucleic acids | 15 |
positive specimens | 15 |
stem cell | 15 |
clinical practice | 15 |
neutralizing antibodies | 15 |
mouse thymic | 15 |
molecular evolutionary | 15 |
serratia species | 15 |
eight patients | 15 |
respiratory infection | 15 |
athymic nude | 15 |
dna extraction | 15 |
murid herpesvirus | 15 |
biomedical research | 15 |
pcr results | 15 |
observed among | 15 |
hospital acquired | 15 |
minimal inhibitory | 15 |
cell count | 15 |
epidemic strains | 15 |
strains resistant | 15 |
uenza virus | 15 |
protective effect | 15 |
complete genomes | 15 |
like particles | 15 |
active infection | 15 |
strain asm | 15 |
breeding colonies | 15 |
airway resistance | 15 |
strains belonged | 15 |
may contribute | 15 |
life sciences | 15 |
structural part | 15 |
latin america | 15 |
renal failure | 15 |
informed consent | 15 |
adaptive immune | 15 |
mhv strains | 15 |
oral dose | 15 |
dendritic cells | 15 |
accession number | 15 |
different concentrations | 15 |
susceptibility patterns | 15 |
nine patients | 15 |
tap water | 15 |
strains exhibited | 15 |
growth medium | 15 |
type iv | 15 |
igm antibodies | 15 |
probiotic strain | 15 |
pulsed field | 15 |
viral metagenomics | 15 |
positive pathogens | 15 |
international committee | 15 |
female mice | 15 |
first step | 15 |
dna sequence | 15 |
mouse genome | 15 |
viral hepatitis | 15 |
binding sites | 15 |
isolates tested | 15 |
medium containing | 15 |
mic range | 15 |
positive patients | 15 |
mvc strains | 15 |
efflux pumps | 15 |
two weeks | 15 |
virus infections | 14 |
lactamase production | 14 |
viral gastroenteritis | 14 |
isolates obtained | 14 |
rnase iii | 14 |
expressed genes | 14 |
va hmo | 14 |
success rates | 14 |
respiratory distress | 14 |
pathogenic strains | 14 |
immunocompromised mice | 14 |
rotavirus strains | 14 |
cefoperazone sulbactam | 14 |
also important | 14 |
dna microarray | 14 |
test program | 14 |
interaction chromatography | 14 |
pneumocystis carinii | 14 |
diagnostic methods | 14 |
pcr reaction | 14 |
promoter region | 14 |
invasive fungal | 14 |
better understanding | 14 |
mammalian cells | 14 |
rrna genes | 14 |
molecular basis | 14 |
difficile toxin | 14 |
clinical outcome | 14 |
natural host | 14 |
human serum | 14 |
humoral immune | 14 |
coronavirus infectious | 14 |
akacid plus | 14 |
differ significantly | 14 |
culture positive | 14 |
colony counts | 14 |
study shows | 14 |
previous study | 14 |
strain vr | 14 |
invasive aspergillosis | 14 |
pcr product | 14 |
lowest mic | 14 |
crucial role | 14 |
aspergillus fumigatus | 14 |
inflammatory bowel | 14 |
old man | 14 |
gene therapy | 14 |
average litter | 14 |
bacterial cells | 14 |
highly active | 14 |
contact time | 14 |
evolutionary genetics | 14 |
conclusion reached | 14 |
animal model | 14 |
whole blood | 14 |
cmv infection | 14 |
murine typhus | 14 |
present work | 14 |
aeruginosa strains | 14 |
strains identified | 14 |
resistance mutations | 14 |
microdilution methods | 14 |
cellular immunity | 14 |
epidemiological studies | 14 |
will also | 14 |
streptococcus agalactiae | 14 |
acquired mrsa | 14 |
primary care | 14 |
innate immunity | 14 |
culture medium | 14 |
last decade | 14 |
expanded broad | 14 |
nucleocapsid protein | 14 |
viral persistence | 14 |
lactobacillus plantarum | 14 |
results indicated | 14 |
virus shedding | 14 |
mean duration | 14 |
breathing maneuvers | 14 |
strains also | 14 |
broad range | 14 |
vast majority | 14 |
metabolic flux | 14 |
virus may | 14 |
physical examination | 14 |
valve endocarditis | 14 |
pitot static | 14 |
diffusion test | 14 |
enterobacter cloacae | 14 |
static probe | 14 |
camp detrick | 14 |
mycobacterium tuberculosis | 14 |
salmonella typhimurium | 14 |
surveillance study | 14 |
poultry industry | 14 |
time point | 14 |
positive culture | 14 |
alternative oxidase | 14 |
antiretroviral therapy | 14 |
fusion protein | 14 |
rna replication | 14 |
viral loads | 14 |
hemorrhagic fever | 14 |
tested positive | 14 |
mixed infections | 14 |
hydrogen peroxide | 14 |
gram stain | 14 |
may play | 14 |
resistance mechanism | 14 |
much higher | 14 |
empiric treatment | 14 |
severe disease | 14 |
medical school | 14 |
affinity chromatography | 14 |
genetic basis | 14 |
pulmonary disease | 14 |
university medical | 14 |
gene segments | 14 |
resistant streptococcus | 14 |
among different | 14 |
newborn mice | 14 |
severe cap | 14 |
hydrophobic interaction | 14 |
also identified | 14 |
high rates | 13 |
culture supernatants | 13 |
multidrug resistance | 13 |
lymph node | 13 |
may explain | 13 |
enzymatic hydrolysis | 13 |
lamina propria | 13 |
sccmec type | 13 |
blot analysis | 13 |
acute bacterial | 13 |
probably due | 13 |
vaccine development | 13 |
clinical failure | 13 |
also tested | 13 |
small number | 13 |
first case | 13 |
ct scan | 13 |
hospital mortality | 13 |
negative pathogens | 13 |
reference laboratory | 13 |
metabolic activity | 13 |
retrospective analysis | 13 |
male mice | 13 |
highly sensitive | 13 |
two major | 13 |
fragilis group | 13 |
ft mic | 13 |
media containing | 13 |
enterica serovar | 13 |
strain showed | 13 |
underlying diseases | 13 |
conducted using | 13 |
antibiotic prescription | 13 |
dba mice | 13 |
interstitial pneumonia | 13 |
producing isolates | 13 |
immune complex | 13 |
first described | 13 |
ill patients | 13 |
time rt | 13 |
serum concentration | 13 |
multivariate analysis | 13 |
bronchitis viruses | 13 |
medical university | 13 |
ch lnm | 13 |
healthy adult | 13 |
affected mice | 13 |
albicans strains | 13 |
recombination event | 13 |
alveolar macrophages | 13 |
four isolates | 13 |
also known | 13 |
infected tissues | 13 |
thymic virus | 13 |
ibv lineages | 13 |
recombinant strains | 13 |
aureus atcc | 13 |
single oral | 13 |
steady state | 13 |
phosphate buffer | 13 |
susceptibility test | 13 |
currently used | 13 |
experimental infections | 13 |
chickens infected | 13 |
antibiotic resistant | 13 |
negative results | 13 |
increased risk | 13 |
human infections | 13 |
start codon | 13 |
atrophic gastritis | 13 |
human norovirus | 13 |
strain respprrs | 13 |
cellular immune | 13 |
eradication rates | 13 |
brain tissue | 13 |
takes place | 13 |
carbapenem resistance | 13 |
rt pcr | 13 |
resistant acinetobacter | 13 |
sentinel mice | 13 |
ng ml | 13 |
live attenuated | 13 |
experimental data | 13 |
differences among | 13 |
severe combined | 13 |
regression model | 13 |
natural conditions | 13 |
plant growth | 13 |
quorum sensing | 13 |
overall mortality | 13 |
strains collected | 13 |
antimicrobial agent | 13 |
significantly associated | 13 |
strains detected | 13 |
efflux pump | 13 |
horizontal transfer | 13 |
days later | 13 |
susceptibility rates | 13 |
clinically important | 13 |
medical records | 13 |
murine encephalomyelitis | 13 |
antimicrobial treatment | 13 |
comparative analysis | 13 |
standard methods | 13 |
ms ms | 13 |
dissolved oxygen | 13 |
pfge patterns | 13 |
metal ions | 13 |
retinal degeneration | 13 |
also detected | 13 |
molecular mechanisms | 13 |
took place | 13 |
diabetic foot | 13 |
cell surface | 13 |
one week | 13 |
correctly identified | 13 |
new species | 13 |
reactive protein | 13 |
may persist | 13 |
southeast asia | 13 |
results also | 13 |
mlsb phenotype | 13 |
data analysis | 13 |
see table | 13 |
dry weight | 13 |
resistant genes | 13 |
ruffled fur | 13 |
patients suffering | 13 |
clustered together | 13 |
confidence intervals | 13 |
cohort study | 13 |
tertiary hospital | 13 |
total protein | 13 |
neurological symptoms | 13 |
adverse event | 13 |
measured using | 13 |
children aged | 13 |
studies showed | 13 |
aeruginosa isolates | 13 |
intranuclear inclusions | 13 |
neurological disease | 13 |
neutropenic patients | 13 |
also resistant | 13 |
human disease | 12 |
sequence similarity | 12 |
acoustic reflection | 12 |
data indicate | 12 |
bacillus cereus | 12 |
heart disease | 12 |
horizontal transmission | 12 |
penicillin resistance | 12 |
hp infection | 12 |
lactamase genes | 12 |
growth hormone | 12 |
children attending | 12 |
human infection | 12 |
specific activity | 12 |
several days | 12 |
using two | 12 |
resistant pneumococci | 12 |
burn wounds | 12 |
species isolated | 12 |
received mg | 12 |
baumannii strains | 12 |
antibiotic policy | 12 |
rapid diagnosis | 12 |
mrna levels | 12 |
negative anaerobic | 12 |
primers used | 12 |
expression vector | 12 |
liquid chromatography | 12 |
food borne | 12 |
inbred mouse | 12 |
infectious complications | 12 |
infectious virus | 12 |
genetically engineered | 12 |
general population | 12 |
hunched posture | 12 |
acid residues | 12 |
type iii | 12 |
future studies | 12 |
spinal cords | 12 |
included patients | 12 |
sequence alignment | 12 |
medical center | 12 |
treatment duration | 12 |
long term | 12 |
pfspz vaccine | 12 |
statistical significance | 12 |
increased significantly | 12 |
chemical synthesis | 12 |
nk cell | 12 |
control subjects | 12 |
first isolated | 12 |
kg ha | 12 |
maternal immunity | 12 |
vancomycin aztreonam | 12 |
viral particles | 12 |
incubation period | 12 |
weaned pups | 12 |
tissue concentration | 12 |
enterotropic mhv | 12 |
widely distributed | 12 |
strains regardless | 12 |
bacterial counts | 12 |
lymphoid tissues | 12 |
wt cmr | 12 |
different genetic | 12 |
natural killer | 12 |
human astrovirus | 12 |
may suggest | 12 |
will help | 12 |
molecular characterisation | 12 |
canary islands | 12 |
human astroviruses | 12 |
strains ck | 12 |
increasing number | 12 |
bacteroides spp | 12 |
clinical outcomes | 12 |
like gene | 12 |
syndrome virus | 12 |
peptide deformylase | 12 |
old female | 12 |
economic losses | 12 |
isolates belonged | 12 |
fluoroquinolone resistance | 12 |
common ancestor | 12 |
toxic shock | 12 |
cytomegalovirus infection | 12 |
slightly higher | 12 |
antibacterial agents | 12 |
agents tested | 12 |
canine astv | 12 |
potent expanded | 12 |
like receptors | 12 |
endothelial cells | 12 |
phage types | 12 |
renal insufficiency | 12 |
mn pv | 12 |
laboratory rat | 12 |
large numbers | 12 |
good correlation | 12 |
enteric disease | 12 |
cranberry juice | 12 |
years ago | 12 |
diagnostic tests | 12 |
ph values | 12 |
heart failure | 12 |
human pathogen | 12 |
cystic oviducts | 12 |
diabetic patients | 12 |
cultures using | 12 |
older mice | 12 |
signs include | 12 |
genetic changes | 12 |
recombinant strain | 12 |
bacterial cell | 12 |
presented data | 12 |
opportunistic infections | 12 |
one day | 12 |
second group | 12 |
gene transfer | 12 |
study included | 12 |
patients undergoing | 12 |
studied period | 12 |
macrolide resistant | 12 |
experimental conditions | 12 |
bovine serum | 12 |
data collection | 12 |
horse blood | 12 |
human isolates | 12 |
rdrp region | 12 |
clinical diagnosis | 12 |
estimate asm | 12 |
batch cultures | 12 |
host genotype | 12 |
daily doses | 12 |
vancomycin resistant | 12 |
reverse genetic | 12 |
porcine reproductive | 12 |
rapid identification | 12 |
bacterial load | 12 |
normal flora | 12 |
scientific research | 12 |
cell density | 12 |
many different | 12 |
white blood | 12 |
species transmission | 12 |
acute care | 12 |
pcr primers | 12 |
low levels | 12 |
single nucleotide | 12 |
serological testing | 12 |
direct detection | 12 |
related infections | 12 |
genetic characterization | 12 |
culture conditions | 12 |
food industry | 12 |
mg tid | 12 |
embryonated eggs | 12 |
meca gene | 12 |
used extensively | 12 |
mechanical properties | 12 |
agarose gel | 12 |
blood group | 12 |
cancer patients | 12 |
tigecycline may | 12 |
embryonic stem | 12 |
monte carlo | 12 |
bp fragment | 12 |
mixed cultures | 12 |
neisseria meningitidis | 12 |
samples collected | 12 |
human malaria | 12 |
young adults | 12 |
cc isolates | 12 |
data set | 12 |
disk synergy | 12 |
infection occurs | 12 |
clinical laboratories | 12 |
signal peptide | 12 |
general practitioners | 12 |
aerobic gram | 12 |
wide spectrum | 12 |
tigecycline compared | 12 |
mice also | 12 |
method using | 12 |
mammary tumors | 12 |
pcr testing | 12 |
metabolic fluxes | 12 |
significantly reduced | 12 |
relationships among | 12 |
savannah river | 12 |
obstructive pulmonary | 12 |
dyspeptic patients | 12 |
resistant staphylococci | 12 |
biochemical tests | 12 |
acid changes | 12 |
genetic elements | 12 |
highly variable | 12 |
found among | 11 |
dilution methods | 11 |
agr group | 11 |
nested pcr | 11 |
higher levels | 11 |
edim virus | 11 |
viral proteins | 11 |
linear regression | 11 |
etiological agent | 11 |
immune cells | 11 |
laboratory tests | 11 |
among others | 11 |
untranslated region | 11 |
lesions include | 11 |
novel genotype | 11 |
presentation will | 11 |
national reference | 11 |
population analysis | 11 |
expanded bed | 11 |
human rotavirus | 11 |
medical faculty | 11 |
see chapter | 11 |
neonatal intensive | 11 |
thermo fisher | 11 |
protective immunity | 11 |
intestinal contents | 11 |
bacterial resistance | 11 |
susceptibility pattern | 11 |
diagnosis diagnosis | 11 |
vitro model | 11 |
encoding genes | 11 |
several genes | 11 |
first line | 11 |
lactobacillus rhamnosus | 11 |
mini kit | 11 |
two days | 11 |
assessed using | 11 |
evaluated using | 11 |
restriction fragment | 11 |
transcription factor | 11 |
deformylase inhibitor | 11 |
prevotella spp | 11 |
contractile capacity | 11 |
samples obtained | 11 |
breeding colony | 11 |
antimicrobial susceptibilities | 11 |
spectrum antibiotics | 11 |
metal resistance | 11 |
opportunistic pathogens | 11 |
nucleotide polymorphisms | 11 |
srs soils | 11 |
cell extracts | 11 |
extraction method | 11 |
histological lesions | 11 |
significant role | 11 |
sample collection | 11 |
forming units | 11 |
esbl producers | 11 |
transmural pressure | 11 |
patients aged | 11 |
dosing interval | 11 |
may contain | 11 |
leading cause | 11 |
capillary electrophoresis | 11 |
dirty bedding | 11 |
aspergillus spp | 11 |
less susceptible | 11 |
early polish | 11 |
primary infection | 11 |
strain co | 11 |
previous reports | 11 |
skin infections | 11 |
type esbls | 11 |
nvp pdf | 11 |
important cause | 11 |
lt produced | 11 |
novel murine | 11 |
among gram | 11 |
duodenal ulcer | 11 |
also present | 11 |
seven strains | 11 |
cell development | 11 |
newly identified | 11 |
also occur | 11 |
local laboratory | 11 |
infection also | 11 |
high incidence | 11 |
structural genes | 11 |
susceptibility profile | 11 |
endemic regions | 11 |
attenuated viruses | 11 |
eliminate infection | 11 |
two times | 11 |
different serotypes | 11 |
physiological state | 11 |
igg anti | 11 |
pulmonary lesions | 11 |
genetics analysis | 11 |
complete sequence | 11 |
effective means | 11 |
control strain | 11 |
long periods | 11 |
high activity | 11 |
tissue sections | 11 |
new drugs | 11 |
vivo experiments | 11 |
infected chickens | 11 |
molecular detection | 11 |
dependent rna | 11 |
data show | 11 |
will provide | 11 |
reovirus infection | 11 |
bat rvas | 11 |
mechanical ventilation | 11 |
nccls broth | 11 |
cutaneous leishmaniasis | 11 |
pilot study | 11 |
norovirus gii | 11 |
bacterial strain | 11 |
immunomodulatory effect | 11 |
spectrum cephalosporins | 11 |
stool specimens | 11 |
wound infections | 11 |
diagnostic accuracy | 11 |
novel astrovirus | 11 |
abdominal infections | 11 |
virulence factor | 11 |
mice experimentally | 11 |
clinical course | 11 |
less likely | 11 |
chronic obstructive | 11 |
time consuming | 11 |
conjugate vaccine | 11 |
nccls recommendations | 11 |
genbank accession | 11 |
energy source | 11 |
different countries | 11 |
different conditions | 11 |
astv strains | 11 |
south america | 11 |
antibiotic prescribing | 11 |
preliminary data | 11 |
sequence comparison | 11 |
lt production | 11 |
different lung | 11 |
significant effect | 11 |
based method | 11 |
yz strains | 11 |
whole organism | 11 |
positive organisms | 11 |
cell tropism | 11 |
selected strains | 11 |
colon cancer | 11 |
extracted using | 11 |
tissue infection | 11 |
reliable therapeutic | 11 |
also included | 11 |
contemporary mouse | 11 |
colonic hyperplasia | 11 |
ad libitum | 11 |
rdrp regions | 11 |
determined according | 11 |
nasal carriage | 11 |
bordetella pertussis | 11 |
care hospitals | 11 |
strains expressing | 11 |
school children | 11 |
tested strains | 11 |
fisher scientific | 11 |
nk cells | 11 |
metabolic network | 11 |
antimicrobial surveillance | 11 |
regression analysis | 11 |
inflammatory lesions | 11 |
positive result | 11 |
every hours | 11 |
biopsy samples | 11 |
bronchoalveolar lavage | 11 |
high dose | 11 |
based methods | 11 |
iu ml | 11 |
common pathogen | 11 |
participating site | 11 |
commonly isolated | 11 |
comparator agents | 11 |
phylogenetic analyses | 11 |
cells grown | 11 |
economic impact | 11 |
transmission events | 11 |
allowed us | 11 |
wheat bran | 11 |
usually subclinical | 11 |
clostridium perfringens | 11 |
parental virus | 11 |
mock infected | 11 |
among clinical | 11 |
common bacterial | 11 |
clinical presentation | 11 |
factors associated | 11 |
allantoic fluid | 11 |
toxin genes | 11 |
white matter | 11 |
producing escherichia | 11 |
nosocomial pathogen | 11 |
isolated strain | 11 |
program determined | 11 |
pcr detection | 11 |
aortic valve | 11 |
ml hg | 11 |
genetically distinct | 11 |
species including | 11 |
many cases | 10 |
histological examination | 10 |
astrovirus strains | 10 |
high quality | 10 |
blister fluid | 10 |
laboratory personnel | 10 |
patient population | 10 |
methicillin resistance | 10 |
parental sex | 10 |
different antibiotics | 10 |
lung inflation | 10 |
eight strains | 10 |
pneumoniae atcc | 10 |
viruses isolated | 10 |
agar medium | 10 |
industrial scale | 10 |
central venous | 10 |
intestinal mucosa | 10 |
patients hospitalized | 10 |
key role | 10 |
free drug | 10 |
culture media | 10 |
invasive disease | 10 |
acute stage | 10 |
emm types | 10 |
studies will | 10 |
hcv infection | 10 |
pneumococcal disease | 10 |
serum levels | 10 |
four times | 10 |
thermal stability | 10 |
lung parenchyma | 10 |
viridans streptococci | 10 |
intestinal microflora | 10 |
river site | 10 |
lesions may | 10 |
two methods | 10 |
past years | 10 |
well established | 10 |
previously identified | 10 |
mlsb resistance | 10 |
transfer rate | 10 |
blood stream | 10 |
wild rats | 10 |
respiratory specimens | 10 |
fragilis strains | 10 |
blood cells | 10 |
microscopic examination | 10 |
ii score | 10 |
pharmacokinetic parameters | 10 |
tandem repeat | 10 |
ampicillin sulbactam | 10 |
spectrum antimicrobial | 10 |
microbiology laboratory | 10 |
lactobacillus reuteri | 10 |
like receptor | 10 |
partial least | 10 |
emergency department | 10 |
moraxella catarrhalis | 10 |
four cases | 10 |
type ibv | 10 |
copy number | 10 |
contaminated food | 10 |
salt concentration | 10 |
univariate analysis | 10 |
ciliated epithelium | 10 |
often used | 10 |
case reports | 10 |
spent grain | 10 |
salmonella enteritidis | 10 |
ii strains | 10 |
blood mononuclear | 10 |
molecular mass | 10 |
virus isolated | 10 |
factors affecting | 10 |
several different | 10 |
east technical | 10 |
significant correlation | 10 |
human cases | 10 |
lesser extent | 10 |
pichia pastoris | 10 |
deduced amino | 10 |
study conducted | 10 |
long axis | 10 |
treponema pallidum | 10 |
chronic hcv | 10 |
oral route | 10 |
children years | 10 |
enterobacteriaceae strains | 10 |
overall incidence | 10 |
drug concentrations | 10 |
metropolitan area | 10 |
related strains | 10 |
screening test | 10 |
high number | 10 |
cell debris | 10 |
months later | 10 |
first detected | 10 |
sample size | 10 |
microarray analysis | 10 |
acquired resistance | 10 |
mean serum | 10 |
bacillus atrophaeus | 10 |
vaccinated chickens | 10 |
crude extract | 10 |
specific genes | 10 |
continuous culture | 10 |
also confirmed | 10 |
functional analysis | 10 |
avian astroviruses | 10 |
six different | 10 |
hearing loss | 10 |
rat colonies | 10 |
gut virome | 10 |
type diabetes | 10 |
strains circulating | 10 |
national research | 10 |
model using | 10 |
using nccls | 10 |
mice treated | 10 |
statistical methods | 10 |
laboratory findings | 10 |
human rva | 10 |
positive predictive | 10 |
generation cephalosporin | 10 |
raw material | 10 |
mean value | 10 |
mrsa prevalence | 10 |
working volume | 10 |
histopathological changes | 10 |
canine astrovirus | 10 |
islamic republic | 10 |
infections may | 10 |
oral microbiology | 10 |
control strains | 10 |
serial passage | 10 |
tinea pedis | 10 |
soil habitat | 10 |
invasive candidiasis | 10 |
protein synthesis | 10 |
field isolates | 10 |
lactis bb | 10 |
genotype i | 10 |
endemic region | 10 |
data showed | 10 |
specific igg | 10 |
levofloxacin mic | 10 |
hospital admission | 10 |
patients diagnosed | 10 |
pneumococcal pneumonia | 10 |
reaction mixture | 10 |
tissue engineering | 10 |
positive effect | 10 |
biological properties | 10 |
major problem | 10 |
commonly encountered | 10 |
generated using | 10 |
resistance levels | 10 |
health status | 10 |
respiratory samples | 10 |
field strains | 10 |
transmissible gastroenteritis | 10 |
degrading enzymes | 10 |
leukemia virus | 10 |
reflection technique | 10 |
gel filtration | 10 |
respiratory system | 10 |
patients included | 10 |
nine strains | 10 |
evolutionary rate | 10 |
renal impairment | 10 |
arthrobacter sp | 10 |
randomized controlled | 10 |
homologous recombination | 10 |
ethics committee | 10 |
also revealed | 10 |
sequence variation | 10 |
animal experiments | 10 |
phage typing | 10 |
icu admission | 10 |
phylogenetic groups | 10 |
hand hygiene | 10 |
detailed analysis | 10 |
body fluids | 10 |
vertical transmission | 10 |
infection due | 10 |
samples taken | 10 |
protease inhibitor | 10 |
dna polymerase | 10 |
north liberty | 10 |
alphitobius diaperinus | 10 |
transplantable tumours | 10 |
fluorescent protein | 10 |
detected using | 10 |
south korea | 10 |
active agents | 10 |
signal transduction | 10 |
severe infection | 10 |
powerful tool | 10 |
growth phase | 10 |
antibacterial effect | 10 |
isolates resistant | 10 |
effective treatment | 10 |
rva human | 10 |
carrier mice | 10 |
many tissues | 10 |
pertussis infection | 10 |
mic determination | 10 |
efflux systems | 10 |
tissue concentrations | 10 |
pathogens including | 10 |
hemagglutinating encephalomyelitis | 10 |
response genes | 10 |
first two | 10 |
eastern europe | 10 |
infection caused | 10 |
genetic backgrounds | 10 |
tw i | 10 |
candida infections | 10 |
slime production | 10 |
enteric pathogens | 10 |
stenotrophomonas maltophilia | 10 |
may reflect | 10 |
ug ml | 10 |
pylori isolates | 10 |
day old | 10 |
chronic hepatitis | 10 |
two phase | 10 |
transmission occurs | 10 |
genetic variation | 10 |
biotechnology institute | 10 |
one year | 10 |
binding capacity | 10 |
polish strains | 10 |
automated system | 10 |
test method | 10 |
agar diffusion | 10 |
strains using | 10 |
weeks later | 10 |
software package | 10 |
acinetobacter baumanii | 10 |
bayesdiallel model | 10 |
sole carbon | 10 |
pharmaceutical industry | 10 |
parental strains | 10 |
coli isolated | 10 |
proinfl ammatory | 10 |
phylogenetic relationships | 10 |
vaccine efficacy | 10 |
glucuronic acid | 10 |
gene revealed | 10 |
genetic heterogeneity | 10 |
clinical use | 10 |
multilocus sequence | 10 |
different media | 10 |
disease severity | 10 |
microbiological analysis | 10 |
liver disease | 10 |
sectional area | 10 |
respiratory symptoms | 10 |
significant association | 10 |
close contact | 9 |
murine coronavirus | 9 |
analysis based | 9 |
pasteurella pneumotropica | 9 |
blood cell | 9 |
commonly associated | 9 |
isolated species | 9 |
two types | 9 |
strains carrying | 9 |
site year | 9 |
insect cell | 9 |
day post | 9 |
lumbar spine | 9 |
stranded dna | 9 |
outpatient antibiotic | 9 |
organic compounds | 9 |
southern china | 9 |
may influence | 9 |
strains will | 9 |
saudi arabia | 9 |
increasing prevalence | 9 |
bacterial dna | 9 |
two distinct | 9 |
shock syndrome | 9 |
immunomodulatory activities | 9 |
enterotropic strains | 9 |
veterinary medicine | 9 |
enteric virus | 9 |
free mice | 9 |
enterococcus sp | 9 |
computed tomography | 9 |
chlamydia trachomatis | 9 |
cause severe | 9 |
using specific | 9 |
supplementary data | 9 |
four major | 9 |
heterologous strains | 9 |
adaptive immunity | 9 |
gastrointestinal infections | 9 |
strain may | 9 |
polish gi | 9 |
eight isolates | 9 |
defined daily | 9 |
consumption rate | 9 |
chmi strains | 9 |
nt aa | 9 |
research centre | 9 |
appropriate use | 9 |
survival rate | 9 |
major source | 9 |
drug classes | 9 |
nucleotide similarity | 9 |
respiratory signs | 9 |
asm bundle | 9 |
intermediate resistance | 9 |
rhamnosus gg | 9 |
immunized group | 9 |
attenuated vaccine | 9 |
urine isolates | 9 |
time period | 9 |
environmental samples | 9 |
pcr analysis | 9 |
benefi cial | 9 |
motor neurons | 9 |
viral pathogens | 9 |
faropenem medoxomil | 9 |
university hospitals | 9 |
invasive infections | 9 |
aureus infections | 9 |
four ibv | 9 |
burn wound | 9 |
conserved among | 9 |
three years | 9 |
lactamase inhibitor | 9 |
lymphoid tissue | 9 |
increasing concentrations | 9 |
mice genetic | 9 |
bacillus sp | 9 |
binding protein | 9 |
rapid development | 9 |
primer pairs | 9 |
results will | 9 |
die within | 9 |
way anova | 9 |
severe cases | 9 |
husbandry practices | 9 |
medical schools | 9 |
new antimicrobial | 9 |
grade i | 9 |
appropriate antibiotic | 9 |
significant decrease | 9 |
prescribed antimicrobials | 9 |
resistance determinant | 9 |
early stages | 9 |
high affinity | 9 |
recently developed | 9 |
often associated | 9 |
typing phage | 9 |
elisa test | 9 |
ciprofloxacin susceptibility | 9 |
melting temperature | 9 |
mouse cytomegalovirus | 9 |
chromosomal dna | 9 |
structural protein | 9 |
viruses may | 9 |
murine hepatitis | 9 |
pfspz strain | 9 |
bacterial prostatitis | 9 |
rd generation | 9 |
pcr ribotype | 9 |
master mix | 9 |
epithelial cell | 9 |
active site | 9 |
blood pressure | 9 |
lung tissue | 9 |
found positive | 9 |
viridans group | 9 |
blood donors | 9 |
resistance development | 9 |
showed significant | 9 |
coronavirus strains | 9 |
resistant gbs | 9 |
within one | 9 |
polyoma virus | 9 |
acquired respiratory | 9 |
mouse serum | 9 |
effi cacy | 9 |
high cell | 9 |
odds ratio | 9 |
underlying conditions | 9 |
environmental serratia | 9 |
one hand | 9 |
isolates carried | 9 |
received grn | 9 |
intestinal epithelium | 9 |
cell tumors | 9 |
puerto rico | 9 |
dairy sheep | 9 |
care centres | 9 |
cpe gene | 9 |
streptococcal colonisation | 9 |
remains unclear | 9 |
transgenic plants | 9 |
affected animals | 9 |
eukaryotic viral | 9 |
relatively resistant | 9 |
yz strain | 9 |
tract pathogens | 9 |
cells ml | 9 |
nasopharyngeal aspirates | 9 |
time periods | 9 |
acute pyelonephritis | 9 |
test using | 9 |
coding sequences | 9 |
environmental contamination | 9 |
showed resistance | 9 |
mic value | 9 |
hcv core | 9 |
eight cases | 9 |
different parts | 9 |
per group | 9 |
much lower | 9 |
canine parvovirus | 9 |
years period | 9 |
different patterns | 9 |
genome analysis | 9 |
pfge profiles | 9 |
identified among | 9 |
enzootically infected | 9 |
ulcerative dermatitis | 9 |
strains vr | 9 |
resistant mutants | 9 |
zone sizes | 9 |
laboratory standards | 9 |
developed countries | 9 |
used antibiotics | 9 |
widespread use | 9 |
blood concentrations | 9 |
primer pair | 9 |
antifungal activity | 9 |
biologically active | 9 |
high mic | 9 |
serum specimens | 9 |
one side | 9 |
optical density | 9 |
maximum likelihood | 9 |
asian strains | 9 |
daily dose | 9 |
quaternary ammonium | 9 |
burgdorferi sensu | 9 |
microbial biotechnology | 9 |
related viruses | 9 |
haemorrhagic fever | 9 |
rva strain | 9 |
sanger sequencing | 9 |
proviral dna | 9 |
house mice | 9 |
fruit bats | 9 |
coli strain | 9 |
guinea pigs | 9 |
high yield | 9 |
fatal disease | 9 |
causative pathogen | 9 |
cell populations | 9 |
brucella melitensis | 9 |
patients showed | 9 |
coli atcc | 9 |
differential expression | 9 |
chronic bronchitis | 9 |
serological monitoring | 9 |
two separate | 9 |
may increase | 9 |
process development | 9 |
difficile isolates | 9 |
group consisted | 9 |
simultaneous detection | 9 |
green fluorescent | 9 |
multiple mechanisms | 9 |
es cell | 9 |
using reverse | 9 |
adenovirus infection | 9 |
toxoplasma gondii | 9 |
children less | 9 |
interspecies transmissions | 9 |
antigenically distinct | 9 |
proteolytic activity | 9 |
antimicrobial consumption | 9 |
diversity among | 9 |
gastric biopsies | 9 |
gastroenteritis virus | 9 |
medical staff | 9 |
definitive diagnosis | 9 |
enteral feeding | 9 |
streptococcal infections | 9 |
different ibv | 9 |
map test | 9 |
pathogenic potential | 9 |
wastewater treatment | 9 |
time kill | 9 |
mean time | 9 |
genes using | 9 |
mn phenotype | 9 |
penicillin susceptibility | 9 |
iia strains | 9 |
murine leukemia | 9 |
homologous chmi | 9 |
different clinical | 9 |
data sets | 9 |
except one | 9 |
positive pcr | 9 |
core antigen | 9 |
several strains | 9 |
field conditions | 9 |
attenuated strains | 9 |
acute diarrhoea | 9 |
two years | 9 |
animal welfare | 9 |
vitro antimicrobial | 9 |
acute flaccid | 9 |
care hospital | 9 |
large amounts | 9 |
compartment model | 9 |
acid identity | 9 |
genomic islands | 9 |
novel method | 9 |
cardiac surgery | 9 |
zoonotic potential | 9 |
wall strain | 9 |
mice showed | 9 |
new technologies | 9 |
mixed infection | 9 |
rodent parvoviruses | 9 |
cause gastroenteritis | 9 |
lactamase inhibitors | 9 |
bact alert | 9 |
mg po | 9 |
commonly prescribed | 9 |
cell mass | 9 |
food poisoning | 9 |
packed bed | 9 |
fine chemicals | 9 |
ndm infected | 9 |
attenuated vaccines | 9 |
previous months | 9 |
china complete | 9 |
give rise | 9 |
experimental design | 9 |
systems biology | 9 |
small airways | 9 |
strain types | 9 |
great potential | 9 |
medical department | 9 |
paediatric patients | 9 |
empirical treatment | 9 |
serovar typhimurium | 9 |
acute exacerbation | 9 |
three independent | 9 |
operating conditions | 9 |
hiv disease | 9 |
tannic acid | 9 |
findings indicate | 9 |
strain ba | 9 |
level gentamicin | 9 |
potent activity | 9 |
virus recovery | 9 |
online version | 9 |
otherwise healthy | 9 |
psoas abscess | 9 |
nsp gene | 9 |
associated diarrhea | 9 |
marine sponges | 9 |
adverse effects | 9 |
strain nrtw | 9 |
amplified using | 9 |
cryptosporidium spp | 9 |
clinical findings | 9 |
study drug | 9 |
new method | 9 |
positive species | 9 |
mrsa infection | 9 |
papn rbd | 9 |
animalis ssp | 9 |
high concentrations | 9 |
serial dilutions | 9 |
bactericidal effect | 9 |
results revealed | 9 |
reference genome | 9 |
animal origin | 9 |
restriction analysis | 9 |
biological samples | 9 |
cell activity | 9 |
clindamycin resistance | 9 |
specific cd | 9 |
highest identity | 9 |
mouse colony | 9 |
suckling piglets | 9 |
fp monooxygenase | 9 |
well documented | 9 |
tested etec | 9 |
new genotype | 9 |
plant species | 9 |
structural variants | 9 |
may affect | 9 |
old male | 9 |
healthy children | 9 |
founder strains | 9 |
clinical setting | 9 |
like strains | 9 |
lt types | 9 |
three heterologous | 9 |
hospital infection | 9 |
ribyz strain | 9 |
malaria vaccine | 9 |
using broth | 9 |
also affect | 9 |
eradication therapy | 9 |
cell types | 9 |
older adults | 9 |
detection kit | 9 |
sea lion | 9 |
two species | 9 |
heilongjiang province | 9 |
neutralizing antibody | 9 |
inhibitory effect | 9 |
tetracycline resistant | 9 |
within weeks | 9 |
aged mice | 9 |
patients died | 9 |
casei dn | 9 |
fq resistance | 9 |
group received | 9 |
magnetic resonance | 9 |
synovial fluids | 8 |
great interest | 8 |
higher mortality | 8 |
cloacal swabs | 8 |
cre recombinase | 8 |
long time | 8 |
bootstrap values | 8 |
sequence types | 8 |
common source | 8 |
enterococcal isolates | 8 |
infected rats | 8 |
electron donor | 8 |
esbl genes | 8 |
type fimbriae | 8 |
vitro assays | 8 |
log reduction | 8 |
airway narrowing | 8 |
plasma cells | 8 |
protein sequence | 8 |
viral respiratory | 8 |
associated infections | 8 |
experimentally induced | 8 |
reassortment events | 8 |
rapid method | 8 |
gastric mucosa | 8 |
medical research | 8 |
bacterial pathogen | 8 |
collected throughout | 8 |
world regions | 8 |
higher proportion | 8 |
sphingobium sp | 8 |
lb broth | 8 |
mdr strains | 8 |
industrial biotechnology | 8 |
pfge types | 8 |
mutation frequency | 8 |
dead space | 8 |
breast milk | 8 |
per bird | 8 |
pivotal role | 8 |
recombinant human | 8 |
well plates | 8 |
six isolates | 8 |
pathogens responsible | 8 |
strains form | 8 |
hbga binding | 8 |
younger adults | 8 |
blood sample | 8 |
body plethysmography | 8 |
chickens challenged | 8 |
successfully treated | 8 |
culture methods | 8 |
epitope sequences | 8 |
gas chromatography | 8 |
intravenous inoculation | 8 |
ambulatory care | 8 |
duck astrovirus | 8 |
bottom cages | 8 |
novel human | 8 |
antiviral therapy | 8 |
heterologous proteins | 8 |
muscle tone | 8 |
receptor binding | 8 |
clinical status | 8 |
vero cell | 8 |
transmissible murine | 8 |
rrna sequencing | 8 |
average age | 8 |
groups according | 8 |
organic solvents | 8 |
environmental isolates | 8 |
antibiotics used | 8 |
research council | 8 |
natural transmission | 8 |
parvovirus infection | 8 |
polymorphic sites | 8 |
production processes | 8 |
sars coronavirus | 8 |
necrotizing pancreatitis | 8 |
brain barrier | 8 |
virulence gene | 8 |
labile toxin | 8 |
giardia muris | 8 |
least days | 8 |
patients presented | 8 |
genetic background | 8 |
inhibitory peptides | 8 |
data support | 8 |